Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001213900-21-008444
Filing Date
2021-02-11
Accepted
2021-02-11 16:00:40
Documents
10

Document Format Files

Seq Description Document Type Size
1 PROSPECTUS ea135201-424b3_aditxtherap.htm 424B3 1552338
2 GRAPHIC image_001.jpg GRAPHIC 7724
3 GRAPHIC image_002.jpg GRAPHIC 52738
4 GRAPHIC image_003.jpg GRAPHIC 67669
5 GRAPHIC image_004.jpg GRAPHIC 56783
6 GRAPHIC image_005.jpg GRAPHIC 40287
7 GRAPHIC image_006.jpg GRAPHIC 33092
8 GRAPHIC image_007.jpg GRAPHIC 32657
9 GRAPHIC image_008.jpg GRAPHIC 81259
10 GRAPHIC image_009.jpg GRAPHIC 8502
  Complete submission text file 0001213900-21-008444.txt   2078991
Mailing Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043
Business Address 2569 WYANDOTTE, ST. SUITE 101 MOUNTAIN CA 94043 909-488-0844
Aditx Therapeutics, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-252711 | Film No.: 21619477
SIC: 2834 Pharmaceutical Preparations